Literature DB >> 29427414

Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza.

Ane Marie Anderson1,2, Marta Baranowska-Hustad1,2, Ranveig Braathen1,2, Gunnveig Grodeland3,2, Bjarne Bogen1,2,4.   

Abstract

There is a need for vaccines that can confer broad immunity against highly diverse pathogens, such as influenza. The efficacy of conventional influenza vaccines is dependent on accurate matching of vaccines to circulating strains, but slow and limited production capacities increase the probability of vaccine mismatches. In contrast, DNA vaccination allows for rapid production of vaccines encoding novel influenza Ags. The efficacy of DNA vaccination is greatly improved if the DNA-encoded vaccine proteins target APCs. In this study, we have used hemagglutinin (HA) genes from each of six group 1 influenza viruses (H5, H6, H8, H9, H11, and H13), and inserted these into a DNA vaccine format that induces delivery of the HA protein Ags to MHC class II molecules on APCs. Each of the targeted DNA vaccines induced high titers of strain-specific anti-HA Abs. Importantly, when the six HA vaccines were mixed and injected simultaneously, the strain-specific Ab titers were maintained. In addition, the vaccine mixture induced Abs that cross-reacted with strains not included in the vaccine mixture (H1) and could protect mice against a heterosubtypic challenge with the H1 viruses A/Puerto Rico/8/1934 (H1N1) and A/California/07/2009 (H1N1). The data suggest that vaccination with a mixture of HAs could be useful for induction of strain-specific immunity against strains represented in the mixture and, in addition, confer some degree of cross-protection against unrelated influenza strains.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29427414      PMCID: PMC5834789          DOI: 10.4049/jimmunol.1701088

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin.

Authors:  H Kawamura; J A Berzofsky
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

3.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

4.  Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.

Authors:  Masanori Terajima; John Cruz; Mary Dawn T Co; Jane-Hwei Lee; Kaval Kaur; Jens Wrammert; Patrick C Wilson; Francis A Ennis
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

5.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

6.  Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection.

Authors:  S B Greenberg; B S Criswell; H R Six; R B Couch
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

7.  Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells.

Authors:  G Hashimoto; P F Wright; D T Karzon
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

8.  Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.

Authors:  Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

9.  Avian influenza A (H5N1) in 10 patients in Vietnam.

Authors:  Tinh Hien Tran; Thanh Liem Nguyen; Thi Dung Nguyen; Thi San Luong; Phuong Mai Pham; van Vinh Chau Nguyen; Thi Suu Pham; Cong Dong Vo; Thi Quynh Mai Le; Thi Thi Ngo; Bach Khoa Dao; Phuc Phat Le; Thanh Truong Nguyen; Thuy Long Hoang; Viet Tung Cao; Truong Giang Le; Dac Tho Nguyen; Hong Nga Le; Kim Tien Nguyen; Hoang San Le; Van Tuan Le; Dolecek Christiane; Tan Thanh Tran; de Jong Menno; Constance Schultsz; Peter Cheng; Wilina Lim; Peter Horby; Jeremy Farrar
Journal:  N Engl J Med       Date:  2004-02-25       Impact factor: 91.245

Review 10.  Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines.

Authors:  Gunnveig Grødeland; Even Fossum; Bjarne Bogen
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

View more
  4 in total

1.  Dendritic Cells Targeting Lactobacillus plantarum Strain NC8 with a Surface-Displayed Single-Chain Variable Fragment of CD11c Induce an Antigen-Specific Protective Cellular Immune Response.

Authors:  Jing Liu; Guilian Yang; Haibin Huang; Chunwei Shi; Xing Gao; Wentao Yang; Zan Zhang; Yang Liu; Ke Xu; Jianzhong Wang; Yuanhuan Kang; Yanlong Jiang; Chunfeng Wang
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

2.  A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza.

Authors:  Ranveig Braathen; Heidi Cecilie Larsen Spång; Daniëla Maria Hinke; Jana Blazevski; Sonja Bobic; Even Fossum; Bjarne Bogen
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-25       Impact factor: 6.698

3.  Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin.

Authors:  Gunnveig Grødeland; Marta Baranowska-Hustad; Justin Abadejos; Tanya R Blane; John Teijaro; David Nemazee; Bjarne Bogen
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

4.  Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief.

Authors:  Tor Kristian Andersen; Johanna Bodin; Fredrik Oftung; Bjarne Bogen; Siri Mjaaland; Gunnveig Grødeland
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.